

# Rossana Roncato

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/4416150/publications.pdf>

Version: 2024-02-01

40  
papers

726  
citations

516215

16  
h-index

580395

25  
g-index

40  
all docs

40  
docs citations

40  
times ranked

944  
citing authors

#	ARTICLE	IF	CITATIONS
1	JAK-Inhibitors for the Treatment of Rheumatoid Arthritis: A Focus on the Present and an Outlook on the Future. <i>Biomolecules</i> , 2020, 10, 1002.	1.8	97
2	Clinical validity of a <i>DPYD</i> -based pharmacogenetic test to predict severe toxicity to fluoropyrimidines. <i>International Journal of Cancer</i> , 2015, 137, 2971-2980.	2.3	70
3	Ubiquitous Pharmacogenomics (U-PCx): The Time for Implementation is Now. An Horizon2020 Program to Drive Pharmacogenomics into Clinical Practice. <i>Current Pharmaceutical Biotechnology</i> , 2017, 18, 204-209.	0.9	51
4	Estimating the Effectiveness of <i>DPYD</i> Genotyping in Italian Individuals Suffering from Cancer Based on the Cost of Chemotherapy-Induced Toxicity. <i>American Journal of Human Genetics</i> , 2019, 104, 1158-1168.	2.6	43
5	Candidate germline polymorphisms of genes belonging to the pathways of four drugs used in osteosarcoma standard chemotherapy associated with risk, survival and toxicity in non-metastatic high-grade osteosarcoma. <i>Oncotarget</i> , 2016, 7, 61970-61987.	0.8	41
6	The Genotype for <i>DPYD</i> Risk Variants in Patients With Colorectal Cancer and the Related Toxicity Management Costs in Clinical Practice. <i>Clinical Pharmacology and Therapeutics</i> , 2019, 105, 994-1002.	2.3	39
7	CDK4/6 Inhibitors in Breast Cancer Treatment: Potential Interactions with Drug, Gene, and Pathophysiological Conditions. <i>International Journal of Molecular Sciences</i> , 2020, 21, 6350.	1.8	34
8	Pregnane X receptor, constitutive androstane receptor and hepatocyte nuclear factors as emerging players in cancer precision medicine. <i>Pharmacogenomics</i> , 2016, 17, 1547-1571.	0.6	31
9	Cost Evaluation of Irinotecan-Related Toxicities Associated With the <i>UGT1A1*28</i> Patient Genotype. <i>Clinical Pharmacology and Therapeutics</i> , 2017, 102, 123-130.	2.3	31
10	Inositol and Non-Alcoholic Fatty Liver Disease: A Systematic Review on Deficiencies and Supplementation. <i>Nutrients</i> , 2020, 12, 3379.	1.7	30
11	Genetic biomarkers for hepatocellular cancer risk in a caucasian population. <i>World Journal of Gastroenterology</i> , 2017, 23, 6674-6684.	1.4	26
12	New Challenges in Tumor Mutation Heterogeneity in Advanced Ovarian Cancer by a Targeted Next-Generation Sequencing (NGS) Approach. <i>Cells</i> , 2019, 8, 584.	1.8	25
13	Association of <i>STAT-3 rs1053004</i> and <i>VDR rs11574077</i> With FOLFIRI-Related Gastrointestinal Toxicity in Metastatic Colorectal Cancer Patients. <i>Frontiers in Pharmacology</i> , 2018, 9, 367.	1.6	24
14	Pharmacogenomics of Targeted Agents for Personalization of Colorectal Cancer Treatment. <i>International Journal of Molecular Sciences</i> , 2017, 18, 1522.	1.8	23
15	NAFLD-Related Hepatocarcinoma: The Malignant Side of Metabolic Syndrome. <i>Cells</i> , 2021, 10, 2034.	1.8	20
16	A Systematic Review and a Meta-Analysis Comparing Prophylactic and Therapeutic Low Molecular Weight Heparins for Mortality Reduction in 32,688 COVID-19 Patients. <i>Frontiers in Pharmacology</i> , 2021, 12, 698008.	1.6	20
17	Cisplatin resistance can be curtailed by blunting Bnip3-mediated mitochondrial autophagy. <i>Cell Death and Disease</i> , 2022, 13, 398.	2.7	20
18	Germline Polymorphisms in the Nuclear Receptors PXR and VDR as Novel Prognostic Markers in Metastatic Colorectal Cancer Patients Treated With FOLFIRI. <i>Frontiers in Oncology</i> , 2019, 9, 1312.	1.3	14

#	ARTICLE	IF	CITATIONS
19	Identification of Novel Somatic TP53 Mutations in Patients with High-Grade Serous Ovarian Cancer (HGSOC) Using Next-Generation Sequencing (NGS). <i>International Journal of Molecular Sciences</i> , 2018, 19, 1510.	1.8	10
20	Clonal Evolution of TP53 c.375+1G>A Mutation in Pre- and Post- Neo-Adjuvant Chemotherapy (NACT) Tumor Samples in High-Grade Serous Ovarian Cancer (HGSOC). <i>Cells</i> , 2019, 8, 1186.	1.8	10
21	Germline and Somatic Pharmacogenomics to Refine Rectal Cancer Patients Selection for Neo-Adjuvant Chemoradiotherapy. <i>Frontiers in Pharmacology</i> , 2020, 11, 897.	1.6	10
22	IL15RA and SMAD3 Genetic Variants Predict Overall Survival in Metastatic Colorectal Cancer Patients Treated with FOLFIRI Therapy: A New Paradigm. <i>Cancers</i> , 2021, 13, 1705.	1.7	10
23	Lipid rafts as viral entry routes and immune platforms: A double-edged sword in SARS-CoV-2 infection?. <i>Biochimica Et Biophysica Acta - Molecular and Cell Biology of Lipids</i> , 2022, 1867, 159140.	1.2	10
24	FARMAPRICE: A Pharmacogenetic Clinical Decision Support System for Precise and Cost-Effective Therapy. <i>Genes</i> , 2019, 10, 276.	1.0	9
25	A TGF- $\beta$ 2 associated genetic score to define prognosis and platinum sensitivity in advanced epithelial ovarian cancer. <i>Gynecologic Oncology</i> , 2020, 156, 233-242.	0.6	5
26	DPYD gene activity score (GAS) predicts dose-limiting toxicity in fluoropyrimidine-treated colorectal cancer patients. <i>Journal of Molecular and Clinical Medicine</i> , 2018, 1, .	0.2	5
27	SMAD3 Host and Tumor Profiling to Identify Locally Advanced Rectal Cancer Patients at High Risk of Poor Response to Neoadjuvant Chemoradiotherapy. <i>Frontiers in Pharmacology</i> , 2021, 12, 778781.	1.6	4
28	Cancer Pharmacogenetics: perspective on newly discovered and implemented predictive biomarkers. , 2021, 3, 357.		3
29	The use of pharmacogenetics to increase the safety of colorectal cancer patients treated with fluoropyrimidines. , 2019, 2, 116-130.		3
30	European association for clinical pharmacology and therapeutics young clinical pharmacologists working group: a cornerstone for the brighter future of clinical pharmacology. <i>European Journal of Clinical Pharmacology</i> , 2022, 78, 691-694.	0.8	3
31	Pharmacogenetic score predicts overall survival, progression-free survival and platinum sensitivity in ovarian cancer. <i>Pharmacogenomics</i> , 2020, 21, 995-1010.	0.6	2
32	Refining neutropenia risk assessment in patients treated with first-line endocrine therapy (ET) and cyclin-dependent kinase 4/6 inhibitors (CDK4/6i) for metastatic breast cancer (MBC) through a cell-free DNA workflow (cfDNA).. <i>Journal of Clinical Oncology</i> , 2021, 39, 1027-1027.	0.8	2
33	Improving decision making on DPYD and <i>UGT1A1</i> *28</i> patientsâ€™ profiling with an innovative reimbursement strategy. <i>Pharmacogenomics</i> , 2018, 19, 301-304.	0.6	1
34	Pre-emptive pharmacogenetic testing implementation for chemotherapy dosage optimization: the translational experience at CRO of Aviano. <i>Annals of Oncology</i> , 2015, 26, vi142.	0.6	0
35	Impact of humoral immune response against p53 on clinical outcome of High-Grade Serous Ovarian Cancer (HGSOC) patients. <i>Annals of Oncology</i> , 2016, 27, viii8.	0.6	0
36	Association of p53-autoantibodies with TP53 somatic mutational profile detected by next generation sequencing in advanced high-grade ovarian cancer. <i>Annals of Oncology</i> , 2017, 28, xi12.	0.6	0

#	ARTICLE	IF	CITATIONS
37	Therapeutic drug monitoring for the cancer patient: challenges and opportunities. , 2021, 3, 591.		0
38	Pharmacovigilance, drug interactions, pharmacogenetics and therapeutic drug monitoring of anticancer agents: a valuable support for clinical practice. , 2021, 3, 550.		0
39	294P Cell-free DNA (cfDNA) workflow for the risk definition of dose-limiting and recurrent neutropenia in patients treated with first-line endocrine therapy (ET) and cyclin-dependent kinase 4/6 inhibitors (CDK4/6i) for metastatic breast cancer (MBC). Annals of Oncology, 2021, 32, S493.	0.6	0
40	Effect of prophylactic and therapeutic low molecular weight heparins on mortality in 15,704 COVID-19 patients. A systematic review and a meta-analysis. European Heart Journal, 2021, 42, .	1.0	0